✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Selpercatinibis the generic ingredient in one branded drug marketed by Loxo Oncol Eli Lilly and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Selpercatinib has eighty patent family members in thirty-seven countries.
One supplier is listed for this compound.
Summary for selpercatinib
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||30|
|What excipients (inactive ingredients) are in selpercatinib?||selpercatinib excipients list|
|DailyMed Link:||selpercatinib at DailyMed|
Recent Clinical Trials for selpercatinib
Identify potential brand extensions & 505(b)(2) entrants
|Massachusetts General Hospital||Phase 2|
|Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company||Phase 1|
|Eli Lilly and Company||Phase 1|
Pharmacology for selpercatinib
|Company||Drugname||Inn||Product Number / Indication||Status||Generic||Biosimilar||Orphan||Marketing Authorisation||Marketing Refusal|
|Eli Lilly Nederland B.V.||Retsevmo||selpercatinib||EMEA/H/C/005375
Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment
|>Company||>Drugname||>Inn||>Product Number / Indication||>Status||>Generic||>Biosimilar||>Orphan||>Marketing Authorisation||>Marketing Refusal|
|Country||Patent Number||Title||Estimated Expiration|
|Moldova, Republic of||3523301||See Plans and Pricing|
|Japan||7153719||See Plans and Pricing|
|Taiwan||201922741||Crystalline forms||See Plans and Pricing|
|Japan||7079303||See Plans and Pricing|
|Eurasian Patent Organization||202090695||КРИСТАЛЛИЧЕСКИЕ ФОРМЫ||See Plans and Pricing|
|European Patent Office||3753939||COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINE EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.